Institutional development · Research, innovation and assessment · Germany
TUM spotlights radiopharmaceutical patented with its hospital for imaging prostate cancer
The Technical University of Munich says a radiopharmaceutical developed and patented at TUM and its university hospital improves visualisation of prostate tumour lesions and supports precise diagnosis.
Why it matters: TUM and TUM University Hospital, where the agent was developed and patented, report a diagnostic tool the university says supports precise prostate cancer diagnosis.
The Technical University of Munich (TUM) reported that a radiopharmaceutical was developed and patented at TUM and TUM University Hospital.
According to TUM, the agent allows tumour lesions to be visualised better and supports precise diagnosis of prostate cancer.
The university notes that about 1.5 million people around the world receive a prostate cancer diagnosis each year.
Editor’s view
Scott James, Research and Innovation Editor
The agent was developed and patented at TUM and TUM University Hospital; if it performs as the university describes, it would support better visualisation of tumour lesions in a disease diagnosed in around 1.5 million people a year.